🧬
FUNCTION-DMD (PBGENE-DMD) · ARCUS® · Exon 45–55 · NCT07429240 · Phase 1/2a · Ages 2–7
IND cleared (FDA Study May Proceed) · Fast Track · Orphan Drug · Rare Pediatric Disease designations · ARCUS homing endonuclease restores dystrophin reading frame via in vivo gene editing.
Priority logic — click any tile to filter
Critical — FUNCTION-DMD, PBGENE-DMD, ARCUS, Precision BioSciences, NCT07429240
High — Exon 45–55 gene editing · FDA BLA/NDA/approval · SEC 8-K DMD companies
Med-high — Named competitors (REGENXBIO, Dyne, Avidity, Wave, Sarepta…)
Medium / Low — All DMD programs, landscape, social mentions
Critical
–
PBGENE-DMD/ARCUS
High
–
Competitor/regulatory
Medium-high
–
Named competitors
Medium
–
DMD landscape
Low
–
Broad mentions
Loading alerts…
Publications
Loading publications…
Keywords
Loading keywords…
Sources
Loading sources…
Logins & API Keys
Credentials are stored encrypted in the database. API keys enable richer social monitoring. Add in priority order: YouTube → Reddit → Meta → Facebook account → LinkedIn → paid sources.
Loading…
Notifications
Email recipients
Digest schedule
Instant alerts (email immediately)
Critical priority alerts
PBGENE-DMD, ARCUS, Precision Bio mentions
High priority alerts
FDA events, SEC filings, competitor PRs
Medium-high alerts
Named competitors, exon 45–55 competitors
Scan Log
Loading scan log…
User Accounts
Roles: Internal (Allele) accounts see all features and settings. Client (Precision Bio) accounts see only reviewed alerts.
Add user
Loading…